APA (7th ed.) Citation

Gordon, K. B., Langley, R. G., Warren, R. B., Okubo, Y., Rosmarin, D., Lebwohl, M., . . . Thaçi, D. (2024). Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: Pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology, 190(4), 477. https://doi.org/10.1093/bjd/ljad429

Chicago Style (17th ed.) Citation

Gordon, Kenneth B., et al. "Bimekizumab Safety in Patients with Moderate-to-severe Plaque Psoriasis: Pooled Data from Up to 3 years of Treatment in Randomized Phase III Trials." British Journal of Dermatology 190, no. 4 (2024): 477. https://doi.org/10.1093/bjd/ljad429.

MLA (9th ed.) Citation

Gordon, Kenneth B., et al. "Bimekizumab Safety in Patients with Moderate-to-severe Plaque Psoriasis: Pooled Data from Up to 3 years of Treatment in Randomized Phase III Trials." British Journal of Dermatology, vol. 190, no. 4, 2024, p. 477, https://doi.org/10.1093/bjd/ljad429.